Talk:Solanezumab

Link
The "Eli Lilly" link should be removed or changed, because it currently points to someone who died in 1898. — Preceding unsigned comment added by 24.217.110.197 (talk) 01:07, 11 December 2013 (UTC)
 * Meanwhile resolved. --ἀνυπόδητος (talk) 11:50, 30 December 2016 (UTC)

potential resource
Pharmaceutical promise "Two monoclonal antibodies to treat Alzheimer’s disease — solanezumab and bapineuzumab—would be a big hit if they reported positive results from phase III trials in 2012. Both bind to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease. Meanwhile, the US Food and Drug Administration will once again consider the thorny issue of approving obesity drugs: it rejected one last year because of worries over side effects. It will also decide whether to approve a pioneering drug for cystic fibrosis, ivacaftor, made by Vertex Pharmaceuticals of Cambridge, Massachusetts. The drug works only for people with a particular genetic mutation, but would be the first to treat the disease’s underlying cause, rather than its symptoms. And blockbuster drugs will continue to lose patent protection, including the anticlotting Plavix (clopidogrel) and the antipsychotic Seroquel (quetiapine)."

Internal links ... 99.181.147.68 (talk) 05:44, 4 January 2012 (UTC)
 * http://www.nature.com/news/2009/080709/full/460164a.html
 * http://www.nature.com/news/2008/121108/full/456161a.html
 * http://www.scientificamerican.com/topic.cfm?id=obesity

Drug names-general comment
Maybe this does not bother anyone else, but I would find it useful to have a phonetic pronounciation guide for the myriad of new drugs that are appearing. MJBennettMD (talk) 02:31, 12 February 2013 (UTC)

Is Sola an official name/abbreviation
If it's not official 'Sola' (used twice in article) should be removed ? - Rod57 (talk) 12:56, 3 July 2015 (UTC)

Health News Reviews
The coverage cited here was the subject of an article in Health News Reviews (with many links):

http://www.healthnewsreview.org/2015/07/taking-stock-of-this-weeks-alzheimers-coverage-a-landmark-breakthrough-that-offers-no-clinically-apparent-benefit/

Taking stock of new Alzheimer’s drug coverage: A “landmark breakthrough” that offers no “clinically apparent benefit”

“The cognitive measures do not have a direct relationship to clinically apparent benefit,” said Dr. Paul Aisen, who is also director of the Alzheimer’s Therapeutic Research Institute at the University of Southern California, speaking to NBC News.

So why bother to present provisional results that don’t even demonstrate that the drugs had any noticeable effect? As Matthew Herper points out at Forbes, the show at this week’s conference may have been more about company stock prices than about informing patients and the public. --Nbauman (talk) 06:52, 1 August 2015 (UTC)
 * Agree. The provisional results and samplings of the over-hypey news coverage were not helpful here. Have trimmed and added some commentary from BMJ.